Denosumab: Clinical Trials

55 trials of Denosumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 9 active not recruiting, 9 unknown, 6 recruiting. 55 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 455Completed 22, Active not recruiting 9, Unknown 9, Recruiting 6, Not yet recruiting 4, Terminated 3, Suspended 1, Withdrawn 1

Follow Denosumab: new trials by email Literature Review of Denosumab trials Research Report on Denosumab

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women
Phase 4Not yet recruitingSahlgrenska University Hospital2162027-01-112026-08-19
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis
Phase 4Not yet recruitingMassachusetts General Hospital1002027-01-012026-11-03
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
Romosozumab, Denosumab - Glucocorticoid-Associated Osteopenia and Osteoporosis
Phase 4Not yet recruitingTuen Mun Hospital542026-09-012026-08-12
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
Denosumab, Romosozumab - Osteoporosis
Phase 4RecruitingNational Taiwan University Hospital902025-12-032025-12-16
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Prolia® - Glucocorticoid-induced Osteoporosis
Phase 4Active not recruitingAmgen1022025-05-242026-05-27
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia) - Osteoporosis in Post-menopausal Women
Phase 4Not yet recruitingMarmara University602025-01-152024-12-27
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months
Romosozumab, Denosumab - Osteoporosis, Glucocorticoids Toxicity
Phase 4CompletedTuen Mun Hospital542024-08-202026-05-05
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
Prolia - Osteoporosis
Phase 4Active not recruitingAmgen1022024-08-062026-02-12
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Denosumab, Saline (0.9% NaCl) - Osteoporosis
Phase 4RecruitingAarhus University Hospital402024-05-212025-12-15
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
Denosumab, Zolendronic Acid - Sarcopenia in Elderly
Phase 4RecruitingPrince of Wales Hospital, Shatin, Hong Kong1202024-04-092026-09-18
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients
alfacalcidol, placebo, Denosumab - Sarcopenia
Phase 4UnknownYonsei University3402024-02-132024-02-22
Preserving Geriatric Muscle With an Osteoporosis Medication
Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion - Osteoporosis
Phase 4RecruitingChrissy Kistler1552024-02-082026-09-23
Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
Eldecalcitol, Native Vitamin D, Denosumab - Osteoporosis in Postmenopausal Women
Phase 4CompletedXi'an Honghui Hospital1002023-08-242025-11-24
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
XGEVA® - Giant Cell Tumor of Bone
Phase 4Active not recruitingAmgen362023-08-172025-10-01
DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Denosumab 120 Mg/1.7 Ml Inj, Placebo - Fibrous Dysplasia, McCune Albright Syndrome
Phase 4RecruitingNatasha Appelman-Dijkstra822023-06-132025-01-29
Muscle Impact of Treating Osteoporosis
Denosumab, Zoledronic Acid, Denosumab Placebo - Sarcopenia, Osteoporosis
Phase 4CompletedNami Safai Haeri202023-02-142026-10-27
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Denosumab, Alendronate Sodium - Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Phase 4CompletedAristotle University Of Thessaloniki722022-12-232026-07-23
Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
Denosumab 60 MG/ML Injectable Solution [Prolia], Placebo - Osteoarthritis, Knee
Phase 4UnknownThe Affiliated Hospital of Qingdao University602022-10-012022-09-29
PRevEnting FracturEs in REnal Disease - 1
Denosumab 60 mg/ml, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate - Kidney Diseases, Dialysis; Complications
Phase 4Active not recruitingWestern University, Canada602022-06-112025-05-31
Anabolic Therapy in Postmenopausal Osteoporosis
Romosozumab, Denosumab - Postmenopausal Osteoporosis
Phase 4Active not recruitingMassachusetts General Hospital502022-03-242026-04-15

Showing 20 of 55. Sign in to see all of them.

Conditions studied

Osteoporosis (27)  ·  Osteoporosis, Postmenopausal (12)  ·  Bone Diseases, Metabolic (4)  ·  Breast Neoplasms (3)  ·  Spinal Cord Injuries (3)  ·  Fractures, Bone (2)  ·  Giant Cell Tumor of Bone (2)  ·  Hyperparathyroidism, Primary (2)  ·  Osteoporotic Fractures (2)  ·  Sarcopenia (2)  ·  Arthralgia (1)  ·  Arthritis, Rheumatoid (1)  ·  Bone Diseases (1)  ·  Bone Resorption (1)  ·  Chronic Kidney Disease-Mineral and Bone Disorder (1)

Sponsors

Massachusetts General Hospital (7)  ·  Amgen (6)  ·  Tuen Mun Hospital (4)  ·  James J. Peters Veterans Affairs Medical Center (3)  ·  Medical University of Vienna (2)  ·  National Taiwan University Hospital (2)  ·  Ottawa Hospital Research Institute (2)  ·  424 General Military Hospital (1)  ·  Aarhus University Hospital (1)  ·  Aristotle University Of Thessaloniki (1)  ·  Chinese University of Hong Kong (1)  ·  Chrissy Kistler (1)  ·  Columbia University (1)  ·  Eli Lilly and Company (1)  ·  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1)

Countries

United States (19)  ·  China (10)  ·  Canada (5)  ·  Poland (3)  ·  Spain (3)  ·  Taiwan (3)  ·  Australia (2)  ·  Austria (2)  ·  Denmark (2)  ·  France (2)  ·  Greece (2)  ·  Hong Kong (2)  ·  South Korea (2)  ·  Sweden (2)  ·  Belgium (1)

Top investigators

Benjamin Leder, MD (3)  ·  Steven C Kirshblum, M.D. (3)  ·  Chi Chiu Mok, MD, FRCP (2)  ·  William A Bauman, M.D. (2)  ·  Antonis Goulas, MD, PhD (1)  ·  Athanasios D Anastasilakis, MD, PhD (1)  ·  Athanasios D Anastasilakis, PhD (1)  ·  Bente Langdahl, MD, Professor, DMSc, PhD (1)  ·  CC Mok (1)  ·  Canan Sanal, Associate Profesor (1)  ·  Changgui Shi, M.D. (1)  ·  Chia-Che Lee (1)  ·  Christian Muschitz, MD (1)

Results publications

PMID 25761434, PMID 25933031, PMID 26327926, PMID 26666998, PMID 27768831, PMID 29024120, PMID 31127467, PMID 31419313, PMID 31447409, PMID 33386953, PMID 34068083, PMID 34231877, PMID 34568375, PMID 39112628, PMID 39527056, PMID 40760465, PMID 40935429, PMID 41058078, PMID 41621431, PMID 42513484, PMID 42786015

NIH funding

2017 (1), P30AG024827 (1), R01AG052123 (1), R01AR073191 (1), R01DK032333 (1)